Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Non-Current Debt: 2018-2022

Historic Non-Current Debt for Theravance Biopharma (TBPH) over the last 3 years, with Jun 2022 value amounting to $396.1 million.

  • Theravance Biopharma's Non-Current Debt rose 5.61% to $396.1 million in Q2 2022 from the same period last year, while for Jun 2022 it was $396.1 million, marking a year-over-year increase of 5.61%. This contributed to the annual value of $371.4 million for FY2021, which is 0.41% down from last year.
  • As of Q2 2022, Theravance Biopharma's Non-Current Debt stood at $396.1 million, which was up 3.11% from $384.2 million recorded in Q1 2022.
  • In the past 5 years, Theravance Biopharma's Non-Current Debt registered a high of $396.1 million during Q2 2022, and its lowest value of $217.7 million during Q2 2019.
  • For the 3-year period, Theravance Biopharma's Non-Current Debt averaged around $378.4 million, with its median value being $375.2 million (2020).
  • Its Non-Current Debt has fluctuated over the past 5 years, first fell by 4.46% in 2019, then skyrocketed by 73.18% in 2020.
  • Quarterly analysis of 5 years shows Theravance Biopharma's Non-Current Debt stood at $229.5 million in 2018, then fell by 4.46% to $219.3 million in 2019, then spiked by 70.03% to $372.9 million in 2020, then decreased by 0.41% to $371.4 million in 2021, then rose by 5.61% to $396.1 million in 2022.
  • Its Non-Current Debt stands at $396.1 million for Q2 2022, versus $384.2 million for Q1 2022 and $371.4 million for Q4 2021.